Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 14/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7193865 | 1.00 | KDM4E (0.48) | KDM4EMEN1KMT2ATACR1CACNA1F | |
| SCHEMBL7193869 | 1.00 | KDM4E (0.48) | KDM4EMEN1KMT2ATACR1CACNA1F | |
| SCHEMBL6541486 | 0.89 | MAPT (0.51) | KDM4EMEN1KMT2ATACR1 | |
| Hydrochloric Acid SCHEMBL6541618 | 0.89 | MAPT (0.48) | KDM4EMEN1KMT2ATACR1CACNA1F | |
| Hydrochloric Acid SCHEMBL6541410 | 0.89 | TACR1 (0.45) | KDM4EMEN1KMT2ATACR1 | |
| Hydrochloric Acid SCHEMBL6540431 | 0.88 | TACR1 (0.46) | KDM4EMEN1KMT2ATACR1 | |
| Hydrochloric Acid SCHEMBL7200288 | 0.88 | TACR1 (0.46) | KDM4EMEN1KMT2ATACR1 | |
| Hydrochloric Acid SCHEMBL7200284 | 0.88 | TACR1 (0.46) | KDM4EMEN1KMT2ATACR1 | |
| Hydrochloric Acid SCHEMBL6541816 | 0.88 | TACR1 (0.50) | KDM4EMEN1KMT2ATACR1 | |
| SCHEMBL7204057 | 0.88 | KDM4E (0.50) | KDM4EMEN1KMT2ATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787543-B2 | PREPARATION OF TACHYKININ ANTAGONISTS; SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030176430-A1 | Benzhydryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176430-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | KDM4E 3697/4885MEN1 629/4885KMT2A 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.